Although East Asians make up a significant share of entry-level roles in U.S. biopharma, few have risen to senior leadership ...

It’s been 19 months since Amgen completed its $27.8 billion acquisition of Horizon Therapeutics, and the California company ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

Akeso's first overall survival readout for its Keytruda challenger caused a violent market reaction. AstraZeneca disclosed ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Far from doffing their caps to actinic keratosis (AK), dermatology drug developers Almirall and Biofrontera are keeping ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and ...

“Under Secretary Kennedy’s leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to ...

Sanofi is racing to raise the flag on meningitis awareness—literally. | This year's 24 Hours of Le Mans endurance car race in ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

As multiple large drugmakers look to navigate trade turbulence by pumping billions of dollars into their U.S. | Eli Lilly CEO ...

In addition to cutting DTC spend, Phathom will also “suspend, defer, or slow” several of its ongoing clinical development ...